247 related articles for article (PubMed ID: 1484319)
21. [Diagnosis of diffuse pleural mesotheliomas].
Loddenkemper R
Pneumologie; 1991 Apr; 45(4):159-61. PubMed ID: 1876593
[TBL] [Abstract][Full Text] [Related]
22. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
Husain AN; Mirza MK; Gibbs A; Hiroshima K; Chi Y; Boumendjel R; Stang N; Krausz T; Galateau-Salle F
Lung Cancer; 2014 Mar; 83(3):324-8. PubMed ID: 24440278
[TBL] [Abstract][Full Text] [Related]
23. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
24. Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas--a clinicomorphological study of 158 cases.
Vortmeyer AO; Preuss J; Padberg BC; Kastendieck H; Schröder S
Anticancer Res; 1991; 11(2):889-94. PubMed ID: 1712181
[TBL] [Abstract][Full Text] [Related]
25. Stereological evaluation of malignant mesothelioma versus benign pleural hyperplasia.
Bogers J; Jacobs W; Segers K; Van Daele A; Weyler J; Van Marck E
Pathol Res Pract; 1996 Jan; 192(1):10-4. PubMed ID: 8685035
[TBL] [Abstract][Full Text] [Related]
26. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].
Chenard-Neu MP; Bellocq JP; Maier A; Batzenschlager A
Ann Pathol; 1990; 10(1):20-7. PubMed ID: 2328062
[TBL] [Abstract][Full Text] [Related]
27. Ultrastructural diagnosis of pleural tumors.
Stoebner P; Brambilla E
Pathol Res Pract; 1982; 173(4):402-16. PubMed ID: 6889732
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations.
Tigrani DY; Weydert JA
Am J Clin Pathol; 2007 Apr; 127(4):580-4. PubMed ID: 17369133
[TBL] [Abstract][Full Text] [Related]
29. [Malignant mesothelioma of the pleura--diagnostic difficulties].
Drozdowska A; Damps-Konstańska I; Kobierska-Gulida G; Madrzak J; Kuziemski K; Pieńkowska J; Ucińska R; Słomiński JM
Pol Merkur Lekarski; 2004 Oct; 17(100):380-1. PubMed ID: 15690708
[TBL] [Abstract][Full Text] [Related]
30. Methods in pathology. p53 expression in formalin-fixed, paraffin-embedded archival specimens of intrahepatic cholangiocarcinoma: retrieval of p53 antigenicity by microwave oven heating of tissue sections.
Terada T; Shimizu K; Izumi R; Nakanuma Y
Mod Pathol; 1994 Feb; 7(2):249-52. PubMed ID: 8008749
[TBL] [Abstract][Full Text] [Related]
31. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
al-Saffar N; Hasleton PS
Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
[TBL] [Abstract][Full Text] [Related]
32. [Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].
Galateau-Salle F
Arch Anat Cytol Pathol; 1993; 41(5-6):212-22. PubMed ID: 8135582
[TBL] [Abstract][Full Text] [Related]
33. β-catenin expression in benign and malignant pleural disorders.
Anani W; Bruggeman R; Zander DS
Int J Clin Exp Pathol; 2011; 4(8):742-7. PubMed ID: 22135721
[TBL] [Abstract][Full Text] [Related]
34. Cadherins, catenins and APC in pleural malignant mesothelioma.
Abutaily AS; Collins JE; Roche WR
J Pathol; 2003 Nov; 201(3):355-62. PubMed ID: 14595746
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glandular lesions of the cervix.
Cina SJ; Richardson MS; Austin RM; Kurman RJ
Mod Pathol; 1997 Mar; 10(3):176-80. PubMed ID: 9071723
[TBL] [Abstract][Full Text] [Related]
36. Role of PCNA in differentiating between malignant mesothelioma and mesothelial hyperplasia: prognostic considerations.
Esposito V; Baldi A; De Luca A; Paciocco G; Gröger A; Sgaramella G; Claudio PP; Giordano GG; Baldi F; Caputi M; Kaiser H; Giordano A
Anticancer Res; 1997; 17(1B):601-4. PubMed ID: 9066586
[TBL] [Abstract][Full Text] [Related]
37. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.
Attanoos RL; Griffin A; Gibbs AR
Histopathology; 2003 Sep; 43(3):231-8. PubMed ID: 12940775
[TBL] [Abstract][Full Text] [Related]
38. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.
Takeda M; Kasai T; Enomoto Y; Takano M; Morita K; Kadota E; Nonomura A
Pathol Int; 2010 May; 60(5):395-9. PubMed ID: 20518890
[TBL] [Abstract][Full Text] [Related]
39. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.
Edwards C; Oates J
J Clin Pathol; 1995 Jul; 48(7):626-30. PubMed ID: 7560168
[TBL] [Abstract][Full Text] [Related]
40. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma.
Sington JD; Morris LS; Nicholson AG; Coleman N
Histopathology; 2003 May; 42(5):498-502. PubMed ID: 12713628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
